Pregabalin pharmacology and its relevance to clinical practice

被引:375
作者
Ben-Menachem, E [1 ]
机构
[1] Univ Gothenburg, Dept Clin Neurosci, Gothenburg, Sweden
关键词
pregabalin; antiepileptic drugs; adjunctive therapy; partial seizures; pharmacology; pharmacokinetics; drug interactions; animal models; alpha-2-delta;
D O I
10.1111/j.0013-9580.2004.455003.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system that exhibits potent anticonvulsant, analgesic, and anxiolytic activity in a range of animal models. In addition, pregabalin has been shown to be a highly effective adjunctive therapy for partial seizures in clinical trials. Potent binding to the alpha-2-delta site reduces depolarization-induced calcium influx with a consequential modulation in excitatory neurotransmitter release. Pregabalin has no demonstrated effects on GABAergic mechanisms. Pregabalin demonstrates highly predictable and linear pharmacokinetics, a profile that makes it easy to use in clinical practice. Absorption is extensive, rapid, and proportional to dose. Time to maximal plasma concentration is similar to1 h and steady state is achieved within 24-48 h. These characteristics reflect the observed onset of efficacy as early as day two in clinical trials. High bioavailability, a mean elimination half life (t(1/2)) Of 6.3 h, and dose-proportional maximal plasma concentrations and total exposures predict a dose-response relationship in clinical practice and allow an effective starting dose of 150 mg/day in clinical practice without need for titration. Administration with food has no clinically relevant effect on the amount of pregabalin absorbed, providing for a dosing regimen uncomplicated by meals. Pregabalin does not bind to plasma proteins and is excreted virtually unchanged (<2% metabolism) by the kidneys. It is not subject to hepatic metabolism and does not induce or inhibit liver enzymes such as the cytochrome P450 system. Therefore, pregabalin is unlikely to cause, or be subject to, pharmacokinetic drug-drug interactions-an expectation that has been confirmed in clinical pharmacokinetic studies. However, dose adjustment may be necessary in patients with renal insufficiency. Thus, the pharmacological and pharmacokinetic profiles of pregabalin provide a predictable basis for its use in clinical practice.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 50 条
  • [31] Matrine: A review of its pharmacology, pharmacokinetics, toxicity, clinical application and preparation researches
    Li, Xia
    Tang, Ziwei
    Wen, Li
    Jiang, Cen
    Feng, Quansheng
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 269
  • [32] Andrographolide: A review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches
    Zeng, Bin
    Wei, Ailing
    Zhou, Qiang
    Yuan, Minghao
    Lei, Kelu
    Liu, Yushi
    Song, Jiawen
    Guo, Li
    Ye, Qiang
    PHYTOTHERAPY RESEARCH, 2022, 36 (01) : 336 - 364
  • [33] Uraria picta: A review on its ethnobotany, bioactive compounds, pharmacology and commercial relevance
    Vats, Sharad
    Kaushal, Chhavi
    Timko, Michael P.
    Ganie, Showkat Ahmad
    SOUTH AFRICAN JOURNAL OF BOTANY, 2024, 167 : 333 - 354
  • [34] The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
    Citrome, Leslie
    Stensbol, Tine Bryan
    Maeda, Kenji
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (10) : 1219 - 1229
  • [35] Clinical pharmacology and pharmacogenetics of thiopurines
    Srikumar Sahasranaman
    Danny Howard
    Sandip Roy
    European Journal of Clinical Pharmacology, 2008, 64 : 753 - 767
  • [36] Clinical pharmacology and pharmacogenetics of thiopurines
    Sahasranaman, Srikumar
    Howard, Danny
    Roy, Sandip
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (08) : 753 - 767
  • [37] Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice
    Nguyen, Thi Van Anh
    Nguyen, Quang Huy
    Nguyen, Tran Nam Tien
    Anthony, Richard M.
    Vu, Dinh Hoa
    Alffenaar, Jan-Willem C.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 62 (04)
  • [38] Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice
    Fogli, Stefano
    Galimberti, Sara
    Gori, Veronica
    Del Re, Marzia
    Danesi, Romano
    PHARMACOLOGICAL RESEARCH, 2021, 167
  • [39] Pregabalin antinociception and its interaction with tramadol in acute model of pain
    Meymandi, Manzumeh Shamsi
    Keyhanfar, Fariborz
    PHARMACOLOGICAL REPORTS, 2012, 64 (03) : 576 - 585
  • [40] Carthami flos: a review of its ethnopharmacology, pharmacology and clinical applications
    Yanhua Tu
    Yingru Xue
    Dandan Guo
    Lianna Sun
    Meili Guo
    Revista Brasileira de Farmacognosia, 2015, 25 : 553 - 566